for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Horizon Therapeutics PLC

HZNP.O

Latest Trade

100.30USD

Change

0.67(+0.67%)

Volume

764,450

Today's Range

97.19

 - 

100.49

52 Week Range

58.06

 - 

103.03

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
99.63
Open
99.33
Volume
764,450
3M AVG Volume
32.36
Today's High
100.49
Today's Low
97.19
52 Week High
103.03
52 Week Low
58.06
Shares Out (MIL)
224.77
Market Cap (MIL)
22,393.69
Forward P/E
27.12
Dividend (Yield %)
--

Next Event

Q2 2021 Horizon Therapeutics PLC Earnings Call

Latest Developments

More

Opko Health Announces Sale Of Its Sterile Fill And Finish Manufacturing Facility In Ireland

Horizon Therapeutics Reports Qtrly Adjusted Earnings Per Share $0.03

Horizon Therapeutics Q4 Sales Rose 105% To $745.3 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Horizon Therapeutics PLC

Horizon Therapeutics plc is a biotechnology company that is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and serious inflammatory diseases. The Company's portfolio is composed of approximately 12 medicines in the areas of rare diseases, gout, ophthalmology and inflammation. The Company has two reportable segments: the orphan and the inflammation segment. The orphan segment includes the medicines TEPEZZA, KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, UPLIZNA and also the Company’s research and development (R&D) programs. TEPEZZA is a monoclonal antibody and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R). KRYSTEXXA is an infused medicine for uncontrolled gout. The Company's other orphan segment medicines, RAVICTI, PROCYSBI and ACTIMMUNE, treats serious chronic diseases. The inflammation segment includes PENNSAID 2%, DUEXIS, RAYOS and VIMOVO medicines.

Industry

Biotechnology & Drugs

Contact Info

Connaught House

1St Floor, 1 Burlington Road

D04 C5Y6

Ireland

+353.1.7722100

https://www.horizontherapeutics.com/

Executive Leadership

Timothy P. Walbert

Chairman of the Board, President, Chief Executive Officer

Paul W. Hoelscher

Chief Financial Officer, Executive Vice President

Irina P. Konstantinovsky

Executive Vice President, Chief Human Resource Officer & Chief Diversity Officer

Barry J. Moze

Executive Vice President, Chief Administrative Officer

Brian K. Beeler

Executive Vice President, General Counsel

Key Stats

1.64 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

1.2K

2019

1.3K

2020

2.2K

2021(E)

2.8K
EPS (USD)

2018

1.830

2019

1.940

2020

3.880

2021(E)

3.673
Price To Earnings (TTM)
86.41
Price To Sales (TTM)
10.24
Price To Book (MRQ)
5.81
Price To Cash Flow (TTM)
39.67
Total Debt To Equity (MRQ)
66.89
LT Debt To Equity (MRQ)
66.48
Return on Investment (TTM)
5.19
Return on Equity (TTM)
4.61

Latest News

Latest News

Dr Reddy's loses bid to invalidate Horizon arthritis drug patents

Indian generic drugmaker Dr Reddy's Laboratories Ltd has lost a bid to invalidate patents on Horizon Therapeutics Plc and Nuvo Pharmaceuticals Inc's arthritis drug Vimovo.

Horizon Therapeutics boosts rare-disease portfolio with $3.05 billion Viela buy

Horizon Therapeutics Plc on Monday agreed to buy Viela Bio Inc for about $3.05 billion in a move to expand its rare-disease portfolio.

Horizon Therapeutics to buy Viela Bio for about $3.05 billion

Horizon Therapeutics said on Monday it will buy drug developer Viela Bio Inc for about $3.05 billion in an all-cash transaction. (Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli)

BRIEF-Horizon Therapeutics - CMS Issues Permanent J-Code For Tepezza Effective Oct 1

* HORIZON THERAPEUTICS PLC - CMS ISSUES PERMANENT J-CODE FOR TEPEZZA (TEPROTUMUMAB-TRBW) EFFECTIVE OCT. 1 Source text for Eikon: Further company coverage:

BRIEF-Hemoshear Therapeutics Achieves Milestone In Exclusive Drug Discovery Collaboration With Horizon Therapeutics In Gout

* HEMOSHEAR THERAPEUTICS ACHIEVES MILESTONE IN EXCLUSIVE DRUG DISCOVERY COLLABORATION WITH HORIZON THERAPEUTICS IN GOUT

BRIEF-Horizon Therapeutics says 79% Patients Achieved Complete Response Using Krystexxa With Methotrexate

* DATA PRESENTED ON KRYSTEXXA® (PEGLOTICASE INJECTION) CO-PRESCRIBED WITH AN IMMUNOMODULATOR ADDS TO GROWING BODY OF EVIDENCE FOR THIS TREATMENT APPROACH

BRIEF-Horizon Therapeutics Announces Redemption Of All $400 Mln of Exchangeable Senior Notes

* HORIZON THERAPEUTICS PLC - ISSUED A NOTICE OF REDEMPTION FOR ALL $400 MILLION OF 2.50% EXCHANGEABLE SENIOR NOTES DUE 2022 Source text for Eikon: Further company coverage:

BRIEF-Horizon Therapeutics Reports Qtrly Loss Per Share of $0.07

* INCREASING 2020 NET SALES GUIDANCE FOR TEPEZZA TO GREATER THAN $200 MILLION FROM $30 MILLION TO $40 MILLION

BRIEF-Horizon Therapeutics PLC Announces Availability Of PROCYSBI

* HORIZON THERAPEUTICS PLC ANNOUNCES AVAILABILITY OF PROCYSBI® (CYSTEAMINE BITARTRATE) DELAYED-RELEASE ORAL GRANULES IN PACKETS IN THE UNITED STATES

BRIEF-Horizon Therapeutics Announces CEO's FY 2019 Total Compensation

* HORIZON THERAPEUTICS PLC SAYS CEO TIMOTHY WALBERT'S FY 2019 TOTAL COMPENSATION WAS $13.9 MILLION VERSUS $16.8 MILLION IN FY 2018 - SEC FILING

BRIEF-India's Lupin Launches Generic Version Of Horizon Therapeutics' Arthritis Drug Vimovo

* LAUNCHES AUTHORIZED GENERIC FOR HORIZON THERAPEUTICS' VIMOVO DELAYED RELEASE TABLETS IN U.S. Source text for Eikon: Further company coverage:

Horizon's prices thyroid eye disease therapy at $14,900 per vial

Horizon Therapeutics Plc on Tuesday priced its treatment for thyroid eye disease at $14,900 per vial following the U.S. FDA approval and said the drug would be available in the United States in the coming weeks.

FDA approves Horizon's drug for thyroid eye disease

The U.S. Food and Drug Administration has approved Horizon Therapeutics Plc's treatment for thyroid eye disease, the agency said on Tuesday.

FDA panel votes unanimously in favor of Horizon's thyroid eye disease drug

Independent advisers to the U.S. Food and Drug Administration on Friday voted unanimously in favor of Horizon Therapeutics Plc's experimental treatment for active thyroid eye disease, taking the drug closer towards potential approval.

FDA panel votes in favour of Horizon's active thyroid eye disease drug

Independent advisers to the U.S. Food and Drug Administration on Friday unanimously voted in favor of Horizon Therapeutics Plc's experimental treatment for thyroid eye disease (TED), taking the drug a step towards potential approval.

IN BRIEF: Fed Circuit shuts down Actavis generic for Horizon’s osteoarthritis drug

Actavis Laboratories UT cannot offer a generic version of Horizon Pharma’s Pennsaid 2% serum until one of the patents on it expires, the U.S. Court of Appeals for the Federal Circuit held Thursday.

Recordati to seek Canadian approval for kidney disease drug

Italy's Recordati said on Tuesday it plans to seek Canadian approval for its drug Cystagon, which treats a rare kidney disease, in a potential blow to Horizon Pharma,, which makes the only drug approved for treatment in Canada.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up